Drug Database
Back to search

United States· US:85248-111_4a4d0c03-7d90-76cb-e063-6394a90a938c

DERMFREE ORIGINAL NASAL

A naphazoline product containing naphazoline hcl, registered in United States by Jiangxi Yudexi Pharmaceutical Co., LTD. The same ATC class is registered in 5 of our 19 countries.

ATC R01AA08US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedDERMFREE ORIGINAL NASALATCR01AA08REGISTER NO.US:85248-111_4a4d0c03…PACKS LISTED2CHECKEDJuly 19, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about naphazoline hclAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Naphazoline is registered in 5 of 19 countries.

Countries holding a registration under ATC R01AA08 (naphazoline), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 3 of them publish a price we can compare per daily dose
Search naphazoline products by name

Naphazoline · ATC R01AA08

5 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Germany
  • Japan
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
NAPHAZOLINE HCL
Manufacturer
Jiangxi Yudexi Pharmaceutical Co., LTD
Country
United States (US)
ATC code
R01AA08
ATC class
Naphazoline
Defined daily dose
0.4 mg, N
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
July 19, 2026

Packs & prices · 2

  • ndc11
    85248-111-01
  • ndc11
    8524811101
    30 mL in 1 BOTTLE (85248-111-01)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

49 interactions on record for naphazoline.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check naphazoline against other medicinesHow interaction checks work

Naphazoline · interactions on record

49 records

  • 6 severe
  • 43 moderate

Most severe, free to view

  • MethylergometrineG02AB01severe
  • DihydroergotamineN02CA01severe
  • ErgotamineN02CA02severe
  • MethysergideN02CA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Naphazoline in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All naphazoline products

Authorised across Europe · EMA

The same active substance is authorised in 18 EEA countries. Names it is sold under:

  • Austria · Aconex, Coldan
  • Czechia · Sanorin
  • Germany · Duraultra N Sine, Rhinex Nasenspray Mit Naphazolin
  • Denmark · Cleareyes
  • Spain · Centilux
  • Finland · Cleari
  • United Kingdom (Northern Ireland) · Clear Eyes, Murine Irritation & Redness Relief
  • Croatia · Nazol, Proculin
  • Hungary · Iridina Due
  • Ireland · Murine Irritation & Redness Relief
  • Iceland · Cleye
  • Italy · Brunizina, Collirio Alfa Decongestionante
  • Latvia · Naphthyzinum
  • Norway · Cleye
  • Romania · Rinofug
  • Sweden · Cleari
  • Slovenia · Proalkalin
  • Slovakia · Sanorin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6245e8e7-31f1-42d6-bc4e-0a6d04738362
GET /v1/drugs/6245e8e7-31f1-42d6-bc4e-0a6d04738362?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "NASAL",
  "source": "ndc",
  "strength": ".05",
  "substance": "NAPHAZOLINE HCL",
  "productndc": "85248-111",
  "dosage_form": "SPRAY",
  "dea_schedule": null,
  "strength_unit": "g/100mL",
  "application_number": "M012",
  "marketing_category": "OTC MONOGRAPH DRUG"
}
API referenceMCP serverPlans

See everything about naphazoline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console